## Edgar Filing: Aeglea BioTherapeutics, Inc. - Form 4

Aeglea BioTherapeutics, Inc. Form 4 March 22, 2017							
					• • • • • •	PPROVAL	
		S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549			N OMB Number:	3235-0287	
Subject to Section 16. Form 4 or Form 5 Filed pure	suant to Section a) of the Public U	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section				Expires: January 31, 2005 Estimated average burden hours per response 0.5	
See Instruction 1(b).	30(h) of the I	nvestment Compar	ny Act of 1	940			
(Print or Type Responses)							
1. Name and Address of Reporting I Rowlinson Scott W	Symbol Aeglea	2. Issuer Name <b>and</b> Ticker or Trading Symbol Aeglea BioTherapeutics, Inc. [AGLE]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (N 901 S. MOPAC EXPRESSWAY, BARTON O PLAZA ONE, SUITE 250	Aiddle) 3. Date (Month/ 03/20/2	of Earliest Transaction Day/Year)		Director X Officer (giv below)		% Owner her (specify	
(Street)		Filed(Month/Day/Year) Applicable Line) _X_ Form filed by O			One Reporting P	int/Group Filing(Check One Reporting Person Iore than One Reporting	
AUSTIN, TX 78746				Person		1 8	
(City) (State)	(Zip) Tal	ole I - Non-Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securit TransactionAcquired Code Disposed (Instr. 8) (Instr. 3, 4) Code V Amount	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
Reminder: Report on a separate line	for each class of sec	curities beneficially ow	ned directly o	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration I (Month/Day	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D	) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Employee Stock Option (right to buy)	\$ 8.03	03/20/2017		А	60,000	<u>(1)</u>	03/19/2027	Common Stock	60,000	

## Edgar Filing: Aeglea BioTherapeutics, Inc. - Form 4

**Reporting Owners** 

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Rowlinson Scott W 901 S. MOPAC EXPRESSWAY BARTON OAKS PLAZA ONE, SUITE 250 AUSTIN, TX 78746			VP, Research			
Signatures						
/s/ Charles N. York II, by power of attorney	03/22/2017					
<u>**</u> Signature of Reporting Person	Da	te				

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The stock option vests and becomes exercisable in 48 equal monthly installments beginning on April 20, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.